Professor Colin Suckling

Research Professor

Pure and Applied Chemistry


Personal statement

Colin Suckling has been Freeland Professor of Chemistry at the University of Strathclyde since 1989. During the 1990s until 2002, he served successively as Dean of the Faculty of Science, Deputy Principal, and Vice Principal of the University of Strathclyde.  Much of Professor Suckling's work during that time was strategic including the development of inter-institutional and interdisciplinary research partnerships notably the research collaboration with the University of Glasgow (WestCHEM), which was recognized publicly with the award of OBE in 2006.

Recent and current research interests focus on the synthesis and properties of heterocyclic compounds designed as molecular probes for biological systems or as drugs.  Particular progress has been made in the field of fused pyrimidine compounds with anticancer and antiparasite activity and in the field of minor groove binders for DNA with antibacterial activity.  Several discoveries are entering pre-clinical development.

Professor Suckling's standing in the field of heterocyclic chemistry has been recognized by the award of the Adrien Albert Lectureship of the Royal Society of Chemistry (2009-10) and his appointment as chairman of the 2011 International Congress of Heterocyclic Chemistry to be held in Glasgow.

Back to staff profile


Strathclyde Minor Groove Binders (S-MGBs) with activity against Acanthamoeba castellanii
McGee Leah MC, Carpinteyro Sanchez Alemao G, Perieteanu Marina, Eskandari Kaveh, Bian Yan, Mackie Logan, Young Louise, Beveridge Rebecca, Suckling Colin J, Roberts Craig W, Scott Fraser J
Journal of Antimicrobial Chemotherapy (2024)
Reduction in creatine metabolites in macrophages exposed to small molecule analogues of the anti-inflammatory parasitic worm product ES-62
Alanazi S, Doonan J, Lumb F E, Alenzi N, Jabbar S, Al-Riyami L, Suckling C J, Harnett W, Watson D G
Parasite Immunology Vol 46 (2024)
MptpB inhibitor improves the action of antibiotics against mycobacterium tuberculosis and nontuberculous mycobacterium avium infections
Rodríguez-Fernández Pablo, Botella Laure, Cavet Jennifer S, Domínguez Jose, Gutierrez Maximiliano G, Suckling Colin J, Scott Fraser J, Tabernero Lydia
ACS Infectious Diseases Vol 10, pp. 170–183 (2024)
Protection against lung pathology during obesity-accelerated ageing in mice by the parasitic worm product ES-62
Harnett Margaret M, Lumb Felicity E, Crowe Jenny, Doonan James, Buitrago Geraldine, Brown Stephanie, Thom Gillian, MacDonald Amy, Suckling Colin J, Selman Colin, Harnett William
Frontiers in Immunology-Inflammation Vol 14 (2023)
The therapeutic potential of drug-like small molecule analogues of the parasitic worm product ES-62 in cerebral small vessel disease
Lumbreras Perales Cristina, Harnett William, Suckling Colin, Scott Fraser, Van Agtmael Tom, Carswell Hilary
6th UK Preclinical Stroke Symposium 2023 (2023)
Do parasitic worm products reverse endothelial dysfunction in cerebral small vessel disease?
Lumbreras Perales Cristina, Suckling Colin, Scott Fraser, Harnett William, Van Agtmael Tom, Carswell Hilary
6th UK Preclinical Stroke Symposium 2023 (2023)

More publications

Back to staff profile

Professional Activities

From blue sky research to big data- external perspectives on making knowledge work
There's no escape - single target, multiple effects
The antibacterial drug, MGB-BP-3, from discovery to clinical trial
Drug discovery backwards -from biological activity to target
Royal Society of Chemistry, North East Region
Invited speaker
International Conference on Chemistry for Mankind: Innovative Ideas in Life Sciences. ICCM-2011
Invited speaker

More professional activities


Novel Therapeutics for the Treatment of Candida infections
Scott, Fraser (Principal Investigator) Hunter, Iain (Co-investigator) Suckling, Colin (Co-investigator)
01-Jan-2023 - 28-Jan-2026
S-MGBs to Treat Invasive and Serious Fungal Diseases (IFDs)
Suckling, Colin (Principal Investigator) Hunter, Iain (Co-investigator) Scott, Fraser (Co-investigator)
01-Jan-2023 - 30-Jan-2024
S-MGBs to Treat Invasive and Serious Fungal Diseases (IFDs)
Scott, Fraser (Principal Investigator) Hunter, Iain (Co-investigator) Suckling, Colin (Co-investigator)
01-Jan-2022 - 30-Jan-2023
Investigating a novel class of Gram-negative active antibiotic suitable for clinical use
Scott, Fraser (Principal Investigator) Hunter, Iain (Co-investigator) Suckling, Colin (Co-investigator) Tucker, Nicholas (Co-investigator)
01-Jan-2020 - 30-Jan-2023
Development of a first-in-class IKKalpha inhibitor for the treatment of castrate resistant p
MacKay, Simon (Principal Investigator) Halbert, Gavin (Co-investigator) Paul, Andrew (Co-investigator) Suckling, Colin (Co-investigator) Watson, David (Co-investigator)
01-Jan-2020 - 31-Jan-2024
Covid-19 Accelerated introduction of a novel class of resistance-proof antiviral drugs: Strathclyde Minor Groove Binders
Scott, Fraser (Principal Investigator) Suckling, Colin (Co-investigator)
01-Jan-2020 - 30-Jan-2020

More projects

Back to staff profile


Professor Colin Suckling
Research Professor
Pure and Applied Chemistry

Tel: 548 2271